Diabetes · DPP-4 Inhibitor and BiguanideRegulatory Approvalregulatorymid-term

FDA Submission for Sitagliptin and Metformin Hydrochloride by Mankind Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Mankind Pharma5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 12:32:51 AM

Assessment confidence: 74% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of Sitagliptin and Metformin Hydrochloride by Mankind Pharma represents a significant regulatory event that could alter the competitive dynamics within the diabetes treatment market. Portfolio teams must evaluate the potential impact on existing products and prepare for shifts in market share and pricing strategies. Regulatory context from FDA (FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 22 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry of this combination therapy and its implications for existing diabetes products. The strongest clinical anchor is A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (ClinicalTrials.gov), sponsor/company relevance (merck). In Diabetes · DPP-4 Inhibitor and Biguanide, 8 regulatory and 3 competitive items passed relevance filtering for Mankind Pharma.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma. This submission may impact the competitive landscape for diabetes treatments, particularly in the DPP-4 inhibitor and biguanide segments.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG) (FDA). Entity match (sitagliptin); Regulatory pathway relevance (nda). The FDA's review of this application will determine the approval timeline and could set precedents for future combination therapies in the diabetes space.

Key Risks

Elevated medium regulatory exposure for Mankind Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this combination therapy could capture market share from existing diabetes treatments, potentially affecting revenue streams for competitors in the DPP-4 inhibitor and biguanide segments.
Upside for Mankind Pharma may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Mankind Pharma may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential market entry of this combination therapy and its implications for existing diabetes products.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and potential approval timeline from the FDA.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves First Oral PCSK9 Inhibitor Lipfendra for High Cholesterol
Humanexa Signalsmedium relevance
Moderate corpus alignment

Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mankind Pharma
Sitagliptin
Metformin Hydrochloride
diabetes treatment market

Commercial impact

medium

If approved, this combination therapy could capture market share from existing diabetes treatments, potentially affecting revenue streams for competitors in the DPP-4 inhibitor and biguanide segments.

Regulatory impact

medium

The FDA's review of this application will determine the approval timeline and could set precedents for future combination therapies in the diabetes space.

What to watch

Monitor the review progress and potential approval timeline from the FDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.